Clincosm LogoSign in Get a demo

minimal residual disease

Showing 1 - 25 of 45
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

Not yet recruiting
  • Multiple Myeloma
  • Minimal Residual Disease
    • (no location specified)
    Nov 1, 2023

    AML, Adult, Minimal Residual Disease Trial (MRD assessment)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • MRD assessment
    • (no location specified)
    Oct 13, 2023

    AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • chidamide and azacitidine
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Sep 27, 2023

    AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

    Not yet recruiting
    • AML, Adult
    • Minimal Residual Disease
    • CD33/CLL1 dual CAR-NK cell
    • +5 more
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Aug 4, 2023

    Rectal Cancer Patients Based on ctDNA-MRD Technology

    Recruiting
    • Rectal Adenocarcinoma
    • +3 more
    • MRD detection
    • Guangzhou, Guangdong, China
      WeiWei Xiao
    Jul 31, 2023

    Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality Trial in São Paulo (Prednisone, Vincristin, Daunorubicin)

    Recruiting
    • Acute Lymphoid Leukemia
    • +3 more
    • São Paulo, SP, Brazil
      Instituto do Cancer do Estado de Sao Paulo
    Jul 24, 2023

    Minimally Residual of Esophageal Cancer 001

    Recruiting
    • Esophageal Carcinoma
    • Minimal Residual Disease
      • Shijiazhuang, Hebei, China
        Fourth Hospital of Hebei Medical University
      Jul 17, 2023

      Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

      Not yet recruiting
      • Minimal Residual Disease
      • Esophageal Squamous Cell Carcinoma
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Jun 10, 2023

        Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

        Not yet recruiting
        • Hematologic Malignancy
        • +21 more
        • (no location specified)
        Feb 9, 2023

        Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

        Recruiting
        • Leukemia, Myeloid, Acute
        • Minimal Residual Disease
          • Chapel Hill, North Carolina
            North Carolina Cancer Hospital (NCCH)
          Feb 2, 2023

          Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

          Recruiting
          • Minimal Residual Disease
          • +11 more
          • ELI-002 2P
          • Duarte, California
          • +10 more
          Jan 18, 2023

          Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

          Suspended
          • Juvenile Myelomonocytic Leukemia
          • +27 more
          • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
          • +2 more
          • Seattle, Washington
            Fred Hutch/University of Washington Cancer Consortium
          Jan 11, 2023

          Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,

          Recruiting
          • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
          • Minimal Residual Disease
          • Goodyear, Arizona
          • +237 more
          Jan 3, 2023

          Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)

          Recruiting
          • Minimal Residual Disease
          • Tianjin, Tianjin, China
            Institute of Hematology & Blood Diseases Hospital
          Nov 3, 2022

          Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

          Not yet recruiting
          • Ph+ ALL
          • +2 more
          • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
          • Tianjin, Tianjin, China
            Institute of Hematology & Blood Diseases Hospital, Chinese Acade
          Oct 30, 2022

          Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

          Recruiting
          • Gastrointestinal Stromal Tumors
          • Minimal Residual Disease
          • liquid biopsy
          • Beijing, Beijing, China
            Peking University People'S Hospital
          Sep 18, 2022

          NSCLC, Minimal Residual Disease, Immunotherapy Trial in Shanghai (sintilimab combined with anlotinib, sintilimab monotherapy)

          Recruiting
          • Non-small Cell Lung Cancer
          • +3 more
          • sintilimab combined with anlotinib
          • sintilimab monotherapy
          • Shanghai, China
            Shanghai Chest Hospital
          Jul 14, 2022

          Acute Myeloid Leukemia in Remission, MDS, Minimal Residual Disease Trial in Germany (Pevonedistat, Azacitidine)

          Active, not recruiting
          • Acute Myeloid Leukemia in Remission
          • +2 more
          • Aachen, Germany
          • +13 more
          Jul 11, 2022

          NSCLC, Metastatic Non Small Cell Lung Cancer, Nsclc Trial in United States (Local ablative therapy, Blood collection to assess

          Recruiting
          • Non-small Cell Lung Cancer
          • +5 more
          • Local ablative therapy
          • Blood collection to assess for ctDNA
          • Basking Ridge, New Jersey
          • +6 more
          Jun 20, 2022

          Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,

          Not yet recruiting
          • Relapsed Acute Myeloid Leukemia
          • +2 more
          • Venetoclax, Decitabine, Azacytidine, Cytarabine
          • (no location specified)
          May 4, 2022

          Better Leukemia Diagnostics Through AI (BELUGA)

          Recruiting
          • Hematologic Malignancy
          • +4 more
          • Automated AI-Guided Diagnosis of Hematological Malignancies
          • Munich, Bavaria, Germany
            MLL Munich Leukemia Laboratory
          Apr 4, 2022

          Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid

          Completed
          • Minimal Residual Disease
          • +3 more
          • Daratumumab
          • +2 more
          • Columbus, Ohio
            Ohio State University Comprehensive Cancer Center
          Mar 2, 2022

          Pediatric ALL, B Cell, Minimal Residual Disease Trial in Seoul (Blinatumomab for Injection)

          Recruiting
          • Pediatric ALL, B Cell
          • Minimal Residual Disease
          • Blinatumomab for Injection
          • Seoul, Korea, Republic of
            Seoul National University Hospital
          Feb 20, 2022

          Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte

          Active, not recruiting
          • Adult Acute Myeloid Leukemia in Remission
          • +12 more
          • Duarte, California
            City of Hope Medical Center
          Feb 17, 2022

          B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease Trial in Vancouver, Halifax

          Terminated
          • B-cell Adult Acute Lymphoblastic Leukemia
          • +2 more
          • blinatumomab
          • Vancouver, British Columbia, Canada
          • +2 more
          Feb 3, 2022